TNF and rheumatoid arthritis: Analysis of serum samples from the ADACTA adalimumab (anti-TNFα) compared with tocilizumab (anti-IL-6R) trial facilitated an assessment of these biomarkers in an inflammatory RA population that not only allowed a direct comparison of clinical response to different targeted therapies within one clinical study, but also avoided confounding effects of concomitant immunosuppression from background methotrexate as this study was conducted using both therapeutic agents as monotherapy [30].